Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA BAUMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619139235
CMS profile
579955
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,945.00

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $2,520.00 2
Ares Trading SA $1,425.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA BAUMAN

NPI 1619139235 · CMS profile ID 579955

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1619139235?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,945.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $630.0011/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142663888 CMS
PFIZER INC. $1,890.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131707098 CMS
Ares Trading SA $1,425.0003/01/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133237825 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,346.90 6
PY2021 $6,402.50 6
PY2022 $2,520.00 1
PY2023 $13,235.53 5
PY2024 $3,945.00 3
PY2025 $4,182.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $662,530.20 43
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $597,434.60 56
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $615,260.38 77
PY2022 Principal investigator $513,473.56 47
PY2021 Principal investigator $536,056.62 88
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $550,482.65 74
PY2019 Principal investigator $501,598.41 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,435.62 12/31/2025 Non-covered Recipient Entity
Fox Chase Cancer Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232927091
Principal investigator 1 Merck Sharp & Dohme LLC $20,600.99 12/31/2025 Non-covered Recipient Entity
Fox Chase Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232937006
Principal investigator 1 Aveo Pharmaceuticals, Inc. $38,770.48 12/08/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910975
Principal investigator 1 Merck Sharp & Dohme LLC $10,050.00 12/01/2025 Non-covered Recipient Entity
Fox Chase Cancer Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232927089
Principal investigator 1 Incyte Corporation $1,000.00 11/24/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240536674
Principal investigator 1 Incyte Corporation $224.00 11/20/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240536678
Principal investigator 1 Aveo Pharmaceuticals, Inc. $32,976.86 11/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910973
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,383.58 11/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910981
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 11/03/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910983
Principal investigator 1 Genmab U.S., Inc. $6,295.50 10/09/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930197
Principal investigator 1 Aveo Pharmaceuticals, Inc. $14,851.89 10/06/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910977
Principal investigator 1 Aveo Pharmaceuticals, Inc. $348.70 10/06/2025 Non-covered Recipient Entity
Institute for Cancer Research
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199910979
Principal investigator 1 Merck Sharp & Dohme LLC $13,175.00 10/02/2025 Non-covered Recipient Entity
Fox Chase Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232937004
Principal investigator 1 Incyte Corporation $1,500.00 09/18/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240536666
Principal investigator 1 Incyte Corporation $1,000.00 09/18/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 1240536671
Principal investigator 1 Aveo Pharmaceuticals, Inc. $14,033.23 09/10/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910945
Principal investigator 1 Organon Llc $1,206.00 09/10/2025 Non-covered Recipient Entity
Institute for Cancer Research
7684-003 No dispute reported 06/30/2026 1173042082
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,123.39 09/08/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910955
Principal investigator 1 Merck Sharp & Dohme LLC $99,907.88 08/31/2025 Non-covered Recipient Entity
Fox Chase Cancer Center-Hematology,Oncology
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation MK-7684A Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer KEYVIBE No dispute reported 06/30/2026 1232917845
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,209.23 08/12/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910943
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,367.01 08/04/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910957
Principal investigator 1 Aveo Pharmaceuticals, Inc. $174.35 07/14/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910941
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,123.39 07/07/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910953
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 06/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910963
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,367.01 06/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910971
Principal investigator 1 Aveo Pharmaceuticals, Inc. $61,496.75 05/20/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910959
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,365.00 05/20/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910965
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,334.79 05/12/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910967
Principal investigator 1 Genmab U.S., Inc. $55,513.05 04/24/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930194
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,300.00 04/16/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910961
Principal investigator 1 Aveo Pharmaceuticals, Inc. $15,144.95 04/11/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910969
Principal investigator 1 Genmab U.S., Inc. $4,932.50 03/20/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930190
Principal investigator 1 Aveo Pharmaceuticals, Inc. $348.70 03/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910939
Principal investigator 1 Aveo Pharmaceuticals, Inc. $15,031.61 03/18/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910951
Principal investigator 1 Genmab U.S., Inc. $931.30 03/06/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930186
Principal investigator 1 Aveo Pharmaceuticals, Inc. $37,899.93 02/11/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910935
Principal investigator 1 Aveo Pharmaceuticals, Inc. $24,021.13 02/03/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910947
Principal investigator 1 Genmab U.S., Inc. $65,226.02 01/30/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930178
Principal investigator 1 Genmab U.S., Inc. $1,500.00 01/09/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930170
Principal investigator 1 Genmab U.S., Inc. $1,000.00 01/09/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930174
Principal investigator 1 Genmab U.S., Inc. $2,000.00 01/09/2025 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235930182
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7.65 01/07/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910937
Principal investigator 1 Aveo Pharmaceuticals, Inc. $21,852.71 01/07/2025 Non-covered Recipient Entity
Institute for Cancer Research
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199910949